

ASX Announcement



Medibio Limited – 9 July 2020

Medibio Announces Entitlement Issue Results

Melbourne, Australia and Minneapolis, MN – 9 July 2020: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCPINK: MDBIF), a health technology company is pleased to advise that the **Fully Underwritten Non-Renounceable Entitlement Offer (Entitlement Offer)** announced by the Company on Wednesday, 10 June 2020 closed on Monday, 6 July 2020.

The Company received applications for 100,263,197 new fully paid ordinary shares amounting to total subscriptions of \$601,579.28. The Underwriter being CPS Capital Group Pty Ltd (**CPS**) has exercised its right to apply for all shortfall shares (including the additional shares applied for under the Entitlement Offer), accordingly no additional shares will be issued to eligible shareholders. Any application for additional shares will be refunded in full.

Below is a table outlining the effects of the Entitlement Issue on the capital structure of the Company:

EVENT	NO. OF SHARES
Shares currently on issue	1,094,796,705
Maximum shares offered under the Entitlement Issue	252,865,843
Shares applied for under the Entitlement Issue	85,533,435
Additional shares applied for under the Entitlement Issue	14,729,762
Shortfall shares to be allocated to CPS	152,602,646
Total shares to be allocated to CPS	167,332,408

The number of shares on issue in the Company after the issue of entitlement shares will be 1,347,662,548.

Managing Director of Medibio, Mr Claude Solitario says: *“I am very thankful to existing shareholders and CPS Capital for their continuing support of Medibio. It is testimony to the hard work and dedication of everyone involved with Medibio that we were able to secure funding, especially in these unprecedented times in light of COVID-19. This funding will allow the Company to continue the commercialisation of ilumen™; the development of the much-anticipated Consumer App; and of course to further advance our trials for the world’s first objective measure for depressive burden. We very much look forward to the period ahead.”.*

If you wish to speak with the Company directly, please contact Mathew Watkins on +61 3 9692 7222.

Claude Solitario
Managing Director and CEO

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited

ASX Announcement



Medibio Limited – 9 July 2020

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.